Results 201 to 210 of about 1,042,347 (367)

Effectiveness and safety of antithrombin for treatment of portal vein thrombosis: Nationwide prospective surveillance of 4 years of clinical experience in Japan

Hepatology Research, EarlyView.
Abstract Aim Antithrombin (AT), a plasma protein with anticoagulant properties, has a long‐standing medical history, primarily for treatment of congenital AT deficiency. Accumulated clinical experiences suggest AT is a potential anticoagulant for thrombotic diseases. This study aimed to clarify the effectiveness, safety, and clinical significance of AT
Shoichi Matsutani, Makoto Arakawa, Susumu Nakano   +2 more
wiley   +1 more source

Genetic Polymorphisms Associated with Prothrombin Time and Activated Partial Thromboplastin Time in Chinese Healthy Population. [PDF]

Genes (Basel), 2022
Zhang F, Mu G, Liu Z, Xie Q, Zhang H, Zhou S, Wang Z, Hu K, Wang Z, Zhao X, Cui Y, Xiang Q.   +11 more
europepmc   +1 more source

Aprotinin Prolongs Whole Blood Activated Partial Thromboplastin Time but Not Whole Blood Prothrombin Time in Patients Undergoing Cardiac Surgery

, 1995
George J. Despotis, Alexander Alsoufiev, Lawrence T. Goodnough, Demetrios G. Lappas   +3 more
openalex   +1 more source

Activated Partial Thromboplastin Time Abnormality in Patients with Cholangiocarcinoma [PDF]

, 2004
Viroj Wiwanitkit
openalex   +1 more source

Thromboelastometry (ROTEM) Assessing Hypercoagulability in Patients Referred for Thrombophilia Screening

International Journal of Laboratory Hematology, Volume 47, Issue 3, Page 520-528, June 2025.
ABSTRACT Introduction Thrombophilia, a blood coagulation disorder, poses risks of venous thromboembolism (VTE). Coagulation assays may not be sufficient to assess VTE risk and global assays such as Rotational Thromboelastometry (ROTEM) may add valuable information.
Mazen Assar, Henning Nilius, Natalie Kearn, Wilma Hopman, Michael Nagler, Maha Othman   +5 more
wiley   +1 more source

Activated Partial Thromboplastin Time and Risk of Future Venous Thromboembolism [PDF]

, 2008
Neil A. Zakai, Tetsuya Ohira, Richard White, Aaron R. Folsom, Mary Cushman   +4 more
openalex   +3 more sources

Differences in the Composition of Activated Partial Thromboplastin Time (APTT) Reagents Affect Clot Waveform Analysis. [PDF]

Yonago Acta Med, 2022
Kato K, Hatayama Y, Shimohiro H, Ichikawa H, Fukuda T.   +4 more
europepmc   +1 more source

Biphasic Activated Partial Thromboplastin Time Waveform and Adverse Events in Non-Intensive Care Unit Patients [PDF]

, 2004
Eve Y. Smith, Linda Charles, Elizabeth M. Van Cott   +2 more
openalex   +1 more source

Activated Protein C Resistance Testing: An Update From Australasia/Asia‐Pacific

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction Activated protein C resistance (APCR) represents a risk factor for thrombosis and is usually due to factor V Leiden (FVL). Clinicians may order either test (i.e., APCR or FVL) to help assess ‘thrombophilia’ in patients who present with thrombosis. APCR testing is usually achieved using clot‐based assays, whereas FVL is assessed by
Emmanuel J. Favaloro, Sandya Arunachalam, Elysse Dean, Mahzuza Salwa, Monica Ahuja, Lynne Connelly, Kent Chapman, Ronny Vong, Leonardo Pasalic   +8 more
wiley   +1 more source

Changes in Some Haemostatic Parameters Among Patients with Chronic Kidney Disease in Kano Metropolis

Sokoto Journal of Medical Laboratory Science, 2017
It has long been accepted that Chronic Kidney Disease (CKD) causes alterations in haemostatic parameters.  These changes have not been reported in our community.
Usman, M. D., *Garba, N., Danladi, S.B., Isah, S.Y., Audu, A., Dakata A.M., and Jelani, I.
doaj